1. Ganoderic acid D is one of the major components in Ganoderma triterpenes. 2. Ganoderic acid D treatment for 48h inhibits the proliferation of HeLa human cervical carcinoma cells with an IC(5) value of 17.3 +/- .3 microM.
Lucideric acid A (Lucidenic acid A) is a modulator of JNK and p38 and enhances LPS-induced immune responses in monocytic THP-1 cells possibly via the modulation of p38 and JNK/MAPKs activation.
Ganoderenic acid D is a natural product isolated from the effective compounds of Ganoderma lucidum extract (GLE). Ganoderenic acid D induces cell cycle arrest and apoptosis and inhibits the proliferation of cancer cells.
1. Ganoderic acid A exhibits antitumor activity, mediated through its inhibitory effect on nuclear transcription factor-kappaB and activator protein-1. 2. Ganoderic acid A can induce proliferation inhibition, apoptosis and suppression of invasion in human
Ganoderic acid F exhibits antitumor and antimetastatic activities through inhibition of angiogenesis and alteration of proteins involving cell proliferation and/or cell death, carcinogenesis, oxidative stress, calcium signaling, and endoplasmic reticulum
Ganoderic acid H is a potent antitumour agent, it mediates its biological effects through the inhibition of transcription factors AP-1 and NF-kappaB, resulting in the down-regulation of expression of Cdk4.
Ganoderic acid B is a chemical marker in quality control of G. lucidum and related products. Ganoderic acid B-containing herbs has potential influence towards therapeutic window of trifluoperazine.Ganoderic acid B has antinociceptive effect
Ganoderic acid C2 has anti-inflammatory,and anti-tumor-promoting activities. Ganoderic acid C2 can inhibit histamine release, it also has inhibitory effects on the induction of Epstein-Barr Virus early antigen.
Ganoderic acid TR, a triterpene compound isolated and exported from the medicinal Ganoderma lucidum, is an inhibitor of H5N1 and H1N1 NAs with broad-spectrum antiviral activity.